The best known is cetuximab, a chimeric IgG1 monoclonal antibody that binds to the extracellular domain of the EGFR membrane and is approved in combination with radiotherapy for the treatment of advanced HNSCC and as monotherapy for locoregional recurrence and metastatic disease. The gene discussed is EGFR; the disease is metastatic neoplasm.